The vaccinia virus (VV) B8R gene encodes a secreted protein with homology to the gamma interferon (IFN-␥) receptor. In vitro, the B8R protein binds to and neutralizes the antiviral activity of several species of IFN-␥, including human and rat IFN-␥; it does not, however, bind significantly to murine IFN-␥. Here we report on the construction and characterization of recombinant VVs (rVVs) lacking the B8R gene. While the deletion of this gene had no effect on virus replication in vitro, rVVs lacking the B8R gene were attenuated for mice. There was a significant decrease in weight loss and mortality in normal mice, and nude mice survived significantly longer than did controls inoculated with parental virus. This is a surprising result considering the minimal binding of the B8R protein to murine IFN-␥ and its failure to block the antiviral activity of this cytokine in vitro. Such reduction in virulence could not be determined in rats, since they are considerably more resistant to VV infection than are mice. Finally, deletion of the B8R gene had no detectable effects on humoral immune responses. Mice and rats vaccinated with the rVVs showed identical humoral responses to both homologous and heterologous genes expressed by VV. This study demonstrates that the deletion of the VV B8R gene leads to enhanced safety without a concomitant reduction in immunogenicity.
Vaccinia virus (VV) is the prototype member of the genus Orthopoxvirus, family Poxviridae, and it has been used extensively as a vector for the development of recombinant live vaccines (34) . There are currently two effective recombinant VV (rVV) vaccines, one for rabies and the other for rinderpest (1, 18, 26, 52, 56) . The rabies rVV vaccine has been used successfully to control fox rabies in Europe and, more recently, raccoon rabies in the United States (38) . The rinderpest rVV vaccine protected cattle from a challenge with more than 1,000 times the lethal dose of the virus (18, 56) . Not all rVVs, however, have been as effective as those for rabies and rinderpest. For example, we showed that rVVs expressing the vesicular stomatitis virus (VSV) G protein (VSV-G) protected against only a minimal experimental challenge dose (33, 57) . Additionally, rhesus macaques immunized with rVVs expressing genes of the simian immunodeficiency virus (SIV) were not protected from virus infection, although there was a reduction in virus load and increased survival time (2, 20, 21, 37) . It is clear that there is a definite need to enhance the efficacy of rVV vaccines against diseases for which protection is not optimal. However, it is even more critical that the safety of rVVs be validated before their approval for use as vaccines. Although VV has not been associated with any disease, it can cause severe complications in immunodeficient or immunosuppressed individuals (6, 7, 15, 43) . Thus, increasing the safety of rVV vaccines without compromising their efficacy is an important consideration in vaccine development.
VV is one of many viruses with genes that code for specific proteins to suppress host immunity. These immunomodulating genes are usually not essential for virus growth in vitro. Their products include homologs of interleukin-1␤ (3, 47) and alpha/ beta interferon (IFN-␣/␤) receptors (14, 49) , complement control proteins (23, 28) , and serine protease inhibitors (8, 25, 29, 46) . In particular, VV contains a gene (B8R) that codes for a secreted protein with sequence similarity to the extracellular domain of the IFN-␥ receptor (50) . This protein neutralizes the antiviral activities of human, rat, rabbit, bovine, and chicken IFN-␥, but it binds with significantly lower affinity to murine IFN-␥ (4, 36, 41, 51) . Cytokines such as IFN-␥ play essential roles in the regulation of the immune system and in defense against pathogens. Additionally, IFN-␥ exhibits adjuvant activities when used with a subunit antigen (5) , and it has attenuating activities (up to 10 6 -fold for immunodeficient mice) when expressed by VV (19, 27) . Thus, we hypothesized that the efficacy as well as the safety of rVVs might be increased by deleting the B8R gene. This hypothesis was tested in mice and rats inoculated with rVVs with a deletion of the B8R gene. We found that rVVs with an inactivated B8R gene are attenuated for normal and nude mice without having a concomitant reduction in immunogenicity.
jected to titer determination in L929 cells. The New Jersey serotype of VSV (55) was propagated and subjected to titer determination in BHK-21 cells.
Animals. Male athymic nude BALB/cBy (nu/nu) mice were purchased from Jackson Laboratory (Bar Harbor, Maine). Female (BALB/c ϫ C57BL/6) F 1 hybrid mice (CB6F 1 ), male athymic nude Rowett (rnu/rnu) rats, and female Fischer 344 (F344) rats were purchased from Harlan Sprague-Dawley (Indianapolis, Ind.). All animals were maintained in accordance with National Institutes of Health guidelines and animal care protocols approved by the Animal Care Committee at the University of California, Davis.
Construction of p2B8R. The strategy used to construct the VV transfer vector p2B8R is shown in Fig. 1 . Each PCR fragment contained engineered restriction endonuclease sites to facilitate vector construction (Table 1) . Briefly, a pUC18 PCR fragment was generated by amplification of plasmid pUC18 (54) with primers pUC18F and pUC18R, which contained the ␤-lactamase gene conferring ampicillin resistance (Amp r ) and the origin of replication (Ori). Next, a B8R left PCR fragment was generated by amplification of VV WR DNA (22, 45) with primers B8R L F and B8R L R, which comprised the region to the left of the B8R gene start codon. This ATG was mutated to an ATA (engineered in the reverse B8R L R primer [shown in lowercase in Table 1 ]) to prevent the expression of a truncated B8R gene. Sequencing of this fragment (comprising most of the B7R gene) with primers B8R L S1, B8R L S2, B8R L S3, and B8R L S4 showed that it contains the wild-type sequence. The pUC18 and B8R left PCR fragments (digested with BglII and KpnI) were ligated to form plasmid pUCB8RLeft. Next, a B8R right PCR fragment, generated with primers B8R R F and B8R R R and containing most of the 819-bp B8R protein coding sequence (nucleotides 157 to 791), was cleaved with BamHI and BglII and ligated to BglII-cleaved pUCB8RLeft, producing pUCB8R. Then a pSC11 (12) PCR fragment (generated with primers pSC11F and pSC11R) was inserted into the BglII site of pUCB8R, resulting in the transfer vector pB8R, which directs the insertion of a cassette containing the VV P 7.5 promoter and the lacZ gene (for ␤-galactosidase expression under the VV P 11 promoter) into the B8R genomic region. Finally, the 273-bp SmaI-XbaI fragment of pB8R (containing the VV P 7.5 promoter) was replaced with the 161-bp SmaI-NheI fragment of pJS5 (13) , generating p2B8R, which contains two back-to-back strong synthetic VV early/late promoters (dsP).
Generation of rVVs and analysis of their genomic DNA, stability, and purity. rVVs were generated by standard homologous recombination using cationic liposome-mediated transfection of BS-C-1 cells infected with the VVs at 0.05 PFU/cell. The rVVs were plaque purified from transfection supernatants on BS-C-1 cell monolayers by using 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-Gal) to detect the lacZ marker gene (16) .
The expression of the lacZ gene by rVVs was tested by cytochemical staining of infected cell monolayers as previously described (32) , with minor modifications. Briefly, plaque assays were performed on BS-C-40 cell monolayers. After 2 days, the cells were rinsed twice with phosphate-buffered saline (pH 7.3) (PBS), fixed with a 2% paraformaldehyde-0.2% glutaraldehyde solution in 0.1 M sodium phosphate (pH 7.3) for 5 min at 4°C, rinsed again with PBS twice, and stained overnight at 37°C with X-Gal stain (0.1 M sodium phosphate [pH 7.3], 1.3 mM MgCl 2 , 3 mM potassium ferricyanide, 3 mM potassium ferrocyanide, 0.1% X-Gal). Next, blue plaques were counted and marked, and finally dishes were stained with crystal violet staining solution (0.5% crystal violet, 10% ethanol, 20% formaldehyde) to reveal any colorless (parental) plaques not marked previously. Restriction analysis of rVV DNA samples was performed with DNA purified by a small-scale method employing micrococcal nuclease (30) .
B8R protein bioassay. B8R protein activity was determined by its ability to prevent the antiviral activity of human IFN-␥. HeLa S3 cell suspensions were infected with rVVs at 20 PFU/cell or mock infected with DMEM for 1 h. The cells were washed twice, resuspended in DMEM, and incubated for 36 h. Supernatants were then harvested, and VV particles were removed by centrifugation at 80,000 ϫ g (24,000 rpm in an SW28 rotor) for 75 min at 4°C on a 25% (wt/wt) sucrose cushion. The clarified supernatant was then concentrated (about 40-fold) with Centriprep-10 concentrators (10,000 molecular weight cutoff) (Amicon, Beverly, Mass.) and filtered through 0.2-m-pore-size filters. Each supernatant was serially diluted in DMEM-5% FBS. Subsequently, 5 l (600 U/ml) of recombinant human IFN-␥ (Genzyme, Cambridge, Mass.) in DMEM-5% FBS was added to 45 l of each dilution and incubated at 37°C for 1 h. Mixtures were then transferred to 96-well plates, seeded 4 to 6 h previously with 2 ϫ 10 4 A549 cells/well in 100 l of DMEM-5% FBS (final IFN-␥ concentration, 20 U/ml). After 24 h of incubation, cells were challenged with the minimum dose of EMCV (10 4 PFU in 50 l) that gave 100% cytopathic effects and stained with crystal violet staining solution 1 day later.
Virus growth curves. Virus replication in vitro was determined by generating one-step growth curves (40) . Briefly, duplicate monolayers of L929 and A549 cells were infected at 0.01 PFU/cell for 1 h in 12-well plates. The cells were then washed and resuspended in 1 ml of DMEM-2.5% FBS. At each time point, supernatants were collected, centrifuged (to pellet detached cells), and transferred to a new tube (the extracellular virus fraction). Cells in the wells were resuspended in 1 ml of DMEM, scraped, and added to the pellet of detached cells (the intracellular virus fraction). The intracellular fraction was freezethawed three times, trypsinized, and sonicated. Duplicates of both virus fractions were subjected to titer determination on BS-C-1 cell monolayers.
Virulence studies in mice and rats. Groups of CB6F 1 normal mice and F344 normal rats (8-to 9-week-old females) were challenged intranasally with 10-fold dilutions (in sterile PBS) of each rVV strain in a final volume of 10 l while under light anesthesia. The animals were examined and weighed daily.
Groups of BALB/cBy nude mice (7-to 8-week-old males) and Rowett nude rats (7-week-old males) were challenged intraperitoneally with 10 7 PFU of each rVV strain in a final volume of 250 l of sterile PBS. The animals were examined daily, and the mortality rate for each group was determined. FIG. 1. Construction of VV transfer vector p2B8R. p2B8R was generated by joining pUC18, B8R left (B8R L ), B8R right (B8R R ), and pSC11 PCR fragments, as well as a DNA fragment from plasmid pJS5. The transfer vector p2B8R directs the insertional inactivation and deletion of the B8R gene of VV by homologous recombination. It contains the lacZ gene for ␤-galactosidase expression under the control of the VV P 11 late promoter for screening of rVVs, and two back-to-back strong synthetic VV promoters (dsP) that are active in both early and late stages of infection. There are multiple cloning sites adjacent to each side of the dsP to facilitate the cloning of heterologous genes (only unique sites are shown).
rVV immunogenicity studies. Groups of animals (6-to 7-week-old female CB6F 1 mice and F344 rats) were immunized intramuscularly with 10 6 PFU of each VV strain in a final volume of 50 l of sterile PBS while under light anesthesia. Serum was collected weekly from each animal, and serum-neutralizing antibody titers to VV and VSV were determined by plaque reduction on BS-C-40 cell monolayers (24) and serum neutralization assays on BHK-21 cell monolayers (33) , respectively.
Data analysis. Statistical analyses were performed using the statistical software program SAS, release 6.11 (SAS Institute, Cary, N.C.).
RESULTS
Deletion of the B8R gene has no effect on VV replication in vitro. The strategy used for generation of the transfer vectors employed in this study is presented in Fig. 1 . rVVs derived from the pB8R transfer vector were unstable, probably due to the presence of P 7.5 in the inverted terminal repeat regions of the VV genome as well as in the transfer vector (25) . For this reason, p2B8R was developed for generating the two rVVs used in this study. The p2B8R transfer vector directs homologous recombination with the B8R region of the VV genome, leading to inactivation of the gene as a result of partial deletion (154 bp) and insertion of the lacZ gene. In addition, its strong synthetic promoters (dsP) allow increased levels of expression (13; P. H. Verardi, F. H. Aziz, S. Ahmad, and T. D. Yilma, unpublished data) of two heterologous genes.
Two rVVs were generated for the study: (i) v⌬B8R was derived from the WR strain of VV, selected because of its high virulence to mice, and (ii) v50⌬B8R was derived from v50, a WR-derived rVV expressing the VSV-G gene within the TK locus (33), selected to facilitate the analysis of the immune response to both homologous (VV) and heterologous (VSV-G) antigens. The purity and stability of the final preparations of viruses were confirmed by X-Gal cytochemical staining of plaques after a minimum of four consecutive plaque purifications in cell culture. Restriction analysis (HindIII digestion) of DNA purified from rVVs confirmed the insertional inactivation of the B8R and TK regions by the lacZ and VSV-G genes, respectively (data not shown). To confirm that the rVVs with a deletion of the B8R gene did not express any residual IFN-␥ binding activities, HeLa S3 cells were infected with the viruses at a high multiplicity of infection (MOI) and their supernatants were harvested, clarified from VV particles, concentrated, and assayed for human IFN-␥-neutralizing activities. It is clear from the data that only the supernatants derived from cells infected with VVs with an intact B8R gene (WR and v50) expressed detectable human IFN-␥-neutralizing activities (Fig.  2) . These concentrated supernatants at dilutions of 1/32 to 1/64 were able to neutralize human IFN-␥ at concentrations of about 20 U/ml; IFN-␥ at 1 U/ml provides 50% protection from cytopathic effects in this assay. However, there were no detectable activities from concentrated supernatants of rVVs lacking the B8R gene, even when undiluted (Fig. 2) .
The plaque phenotypes of rVVs and their parental strains were indistinguishable in cell culture. Similarly, the growth of all viruses in vitro (at low MOI) was essentially identical (Fig.  3) . This was true for viruses grown in human (A549) or murine (L929) cells and for both intracellular and extracellular virus fractions (Fig. 3) . Infection at higher MOIs also resulted in virtually identical virus yields (data not shown). Thus, the deletion of the B8R gene has no effect on virus replication in vitro.
Deletion of the B8R gene decreases VV virulence for normal mice. Immunocompetent mice inoculated intranasally with 10 3 FIG. 2. Human IFN-␥-neutralizing activities of VV-infected cell supernatants. Supernatants of HeLa S3 cells infected with the rVVs at 20 PFU/cell or mock infected with DMEM were collected 36 h postinfection, clarified, concentrated, and assayed for their ability to inactivate the antiviral activity of human IFN-␥. Recombinant human IFN-␥ (5 l, 600 U/ml) was added to 45 l of serial dilutions of each supernatant, and the mixtures were incubated at 37°C for 1 h and then transferred to A549 cell monolayers in 96-well plates (final IFN-␥ concentration, 20 U/ml). After 24 h, the cells were challenged with EMCV; they were stained with crystal violet 1 day later. Control wells received equivalent volumes of DMEM in lieu of cell supernatants (all controls), human IFN-␥ (EMCV and cell controls), and EMCV challenge (cell control). Assays were performed in duplicate with identical results (only one plate is shown). 5 PFU of WR had marked weight loss, which was not observed in v⌬B8R-infected mice (Fig. 4A) . This difference was statistically significant (by analysis of variance [ANOVA]) from days 5 through 21 postinfection (P Ͻ 0.05) and highly significant on days 7, 8, and 9 postinfection (P Ͻ 0.001). When v⌬B8R was used at a dose of 10 6 PFU, no significant weight loss was observed, while mice inoculated with 10 6 PFU of WR showed marked weight loss (data not shown) and one of them died (20% mortality [Fig. 4B]) . Finally, when v⌬B8R was used at a dose of 10 7 PFU, the mice had some weight loss (data not shown) but survived, while three of the mice inoculated with 10 7 PFU of WR died (60% mortality). This difference in survival was significant (P Ͻ 0.05, log-rank test). Taken together, these results indicate that inactivation of the B8R gene decreases VV virulence for mice. On the other hand, rats inoculated intranasally with doses as high as 10 7 PFU of either WR or v⌬B8R did not have significant weight loss or any other signs of disease and maintained normal growth curves (data not shown).
Deletion of the B8R gene attenuates VV virulence for nude mice. Immunodeficient, athymic nude mice inoculated intraperitoneally with 10 7 PFU of v50⌬B8R displayed a significantly greater (P Ͻ 0.001, Mann-Whitney-Wilcoxon test) survival rate than did nude mice inoculated with v50 (Fig. 5) . While all nude mice injected with v50 died by 23 days postinfection, mice infected with v50⌬B8R had a survival rate of 89% on this day (Fig. 5) . The median survival time of nude mice inoculated with v50 and v50⌬B8R was 13 and 29 days, respectively. All nude mice inoculated with v50 and v50⌬B8R developed typical pox lesions. A group of four control nude mice mock inoculated with sterile PBS remained healthy throughout the observation period of 120 days. Nude rats inoculated intraperitoneally with 10 7 PFU of VV resisted infection, showing no signs of disease (including pox lesions) even when injected with the highly virulent WR strain (data not shown).
Deletion of the B8R gene does not alter the humoral response to VV. Groups of normal mice and rats (five animals/ group) were inoculated intramuscularly with 10 6 PFU of VV. Serum was collected weekly from each animal, and neutralizing-antibody titers to VV and VSV were determined by a plaque reduction assay or serum neutralization, respectively. Although there was a significant increase in attenuation, no statistical differences were observed in the humoral immune response to either homologous (VV) or heterologous (VSV-G) antigens in mice or rats inoculated with rVVs (Fig. 6) .
DISCUSSION
VV is one of many viruses that code for immunomodulating proteins, including B8R. This secreted protein has sequence similarity to the extracellular domain of the IFN-␥ receptor, binding and neutralizing the antiviral activity of most species of IFN-␥, including rat IFN-␥. However, even at high concentrations, the B8R protein fails to block the antiviral activity of murine IFN-␥ in vitro (4, 36, 41, 51) . IFN-␥ is a pleiotropic cytokine that plays essential roles in the regulation of the immune system and in the host defense against pathogens. We and others showed that rVVs expressing IFN-␥ were attenuated by more than 10 6 -fold in immunodeficient mice (19, 27) and that IFN-␥ has adjuvant activities when used with a subunit antigen (e.g., VSV-G) (5) . This led us to the hypothesis that deleting immunomodulating genes (e.g., the B8R gene) in rVVs would allow the development of safer and more efficacious vaccines.
To test our hypothesis, we constructed two rVVs with deleted B8R genes to test the role of this gene in virulence and on the humoral immune response of animals to both homologous (VV) and heterologous (VSV-G) antigens. Although the B8R protein does not inhibit the antiviral activity of murine IFN-␥ (4, 36, 41, 51) and has no effect on VV replication in vitro (Fig. 3) , inactivation of the B8R gene reduced the virulence of VV in a murine intranasal model (as measured by weight loss and survival rates of normal mice) and in a nude mouse model (as measured by survival rates of nude mice). Intranasal infection of normal mice with rVVs has been reported to be an ideal route for studies of pathogenesis and virulence (53) , and CB6F 1 mice have been used extensively to assess the adjuvant activity of IFN-␥ (39). It has also been reported that rVVs with an insertional inactivation of the TK gene (i.e., v50 and v50⌬B8R) are greatly attenuated for normal mice (10); doses as high as 5 ϫ 10 6 PFU of v50 failed to cause weight loss in CB6F 1 mice (P. H. Verardi, F. H. Aziz, and T. D. Yilma, unpublished data). For this reason, only WR and v⌬B8R (with a higher starting virulence) were used in the virulence studies in immunocompetent mice. Normal mice inoculated intranasally with WR had significantly higher weight loss and mortality than did v⌬B8R-infected mice (Fig. 4) . These results indicate that the inactivation of the B8R gene attenuates VV virulence for mice. On the other hand, such reduction in virulence could not be determined in normal rats, since they are considerably more resistant to VV infection than mice (F344 rats infected with either WR or v⌬B8R did not lose weight or exhibit disease symptoms even when the virus was given at a dose of 10 7 PFU). Intraperitoneal inoculation of nude mice is an established model for disseminated VV infection (17, 19, 42) . Since VVs with an intact TK gene are highly virulent for nude mice, only v50 and v50⌬B8R (with a lower starting virulence) were used in the attenuation studies with immunodeficient mice. We demonstrated that nude mice inoculated with v50⌬B8R had significantly higher survival rates than did those inoculated with v50 (Fig. 5) . The effects of the B8R protein could not be determined in nude rats due to their greater resistance to VV infection (44) . The direct inactivation of the antiviral activity of murine IFN-␥ by the B8R protein cannot explain the higher virulence of rVVs with an intact B8R gene, since the B8R protein does not bind significantly to murine IFN-␥ in vitro. Knockout mice with an inactivated IFN-␥ receptor gene were found to be more susceptible to infection with VV or herpesvirus than were mice with an inactivated IFN-␥ gene (11) , although one would assume that the two groups of mice would be equally susceptible. This suggests that there may be more than one ligand for the IFN-␥ receptor and its poxvirus homologs. Indeed, the myxoma virus homolog of the B8R protein (M-T7), which was shown to be a virulence factor in rabbits (35) , has a number of ligands including rabbit IFN-␥ and human interleukin-8; it also inhibits the biological activity of the chemokine RANTES (31) . In addition, VVs expressing human IFN-␥ are attenuated for nude mice (19) . This is surprising since human IFN-␥ has no detectable antiviral activity in mouse cells. Thus, it is reasonable to deduce that the B8R protein may bind to other immunoregulatory proteins or may have immunomodulating properties in vivo that affect VV virulence by a mechanism other than direct interference with the antiviral activity of IFN-␥.
B8R-deleted rVVs elicited humoral immune responses to both homologous (VV) and heterologous (VSV-G) antigens that did not differ significantly from those of the respective parental strains (Fig. 6 ). One could speculate that the deletion of the B8R gene would augment the immune response by eliminating immunomodulating functions of the B8R protein (e.g., binding IFN-␥ to neutralize its antiviral activity), just as the deletion of serine protease inhibitor homolog genes of VV increases antibody response to a heterologous antigen (58) . However, we have shown here that the B8R gene also acts as a virulence factor; its deletion attenuates the vector, which should result in a decreased immune response. The two competing actions could effectively cancel each other, accounting for the experimental observation that humoral immune responses elicited by both B8R ϩ and B8R Ϫ viruses are essentially the same. In future studies, it will be of great interest to determine the effect of the B8R gene in cell-mediated immune responses, which are essential to vaccine efficacy.
Two highly effective rVV vaccines have been developed to date: one for protection against rinderpest and the other for the eradication of rabies in wildlife (1) . However, other rVVs have not been as efficacious. Also, the safety of rVVs is a major concern, especially for immunocompromised individuals. Strategies to increase safety include the use of modified VV FIG. 6 . Immunogenicity studies of VV-infected immunocompetent mice and rats. Groups of five normal mice (CB6F 1 ) (A and C) or rats (F344) (B and D) were inoculated intramuscularly with 10 6 PFU of WR, v⌬B8R, v50, or v50⌬B8R. Each histogram represents the mean serum neutralizing-antibody titer to VV (A and B) or VSV (C and D). Serum samples were pooled and assayed in duplicate, except for the experiment in panel D, where samples were assayed individually (error bars represent the standard error of the mean). Undetectable levels of VV and VSV serum neutralizing antibodies (Ͻ8) were found at the time of inoculation for all groups (week 0), for all time points in a group of mice mock inoculated with sterile PBS, and for the VSV titers of WR-and v⌬B8R-infected animals (data not shown). One v50-inoculated mouse died of undetermined causes 36 days postinfection. Ankara (MVA), a highly attenuated and host cell-restricted vector (37, 48) . Here we show that the B8R protein is a VV virulence factor in mice despite the lack of detectable inhibition of the antiviral activity of murine IFN-␥ by the B8R protein in vitro. In addition, deletion of the B8R gene did not alter the immune responses to homologous (VV) or heterologous (VSV-G) antigens. Consequently, the B8R locus emerges as an excellent site for heterologous gene expression in rVV vaccine development; inactivation of the B8R gene attenuates VV (increasing the safety of the vector) without compromising the effectiveness of the immune response elicited by the recombinant vaccine. All of these features are highly desirable for the development of new, effective rVV vaccines.
